Full Text View
Tabular View
No Study Results Posted
Related Studies
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
This study has been completed.
Study NCT00003819   Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999   Last Updated: April 3, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
QS21
TF(c)-KLH conjugate vaccine
Thomsen-Friedenreich antigen
keyhole limpet hemocyanin
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
Keyhole-limpet hemocyanin
QS 21
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services